SCHEMBL6068013

SCHEMBL6068013

CCNC(=O)Nc1nc2ccc(/C=C\c3ccccc3)cc2s1

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 11/20 0.70
NPC1 O15118 5/20 0.66
RAB9A P51151 5/20 0.66
SMN1; SMN2 Q16637 4/20 0.66
PIK3CA P42336 1/20 0.53
PIK3CG P48736 1/20 0.53
MEN1 O00255 1/20 0.52
USP2 O75604 1/20 0.52
POLB P06746 1/20 0.52
MAPT P10636 1/20 0.52
KMT2A Q03164 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
PIK3CD O00329 1/20 0.52
FSCN1 Q16658 1/20 0.51
DYRK1A Q13627 1/20 0.50
DYRK1B Q9Y463 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6068016 1.00 ABL1 (0.70) ABL1NPC1RAB9ASMN1; SMN2PIK3CA
SCHEMBL6068008 1.00 ABL1 (0.70) ABL1NPC1RAB9ASMN1; SMN2PIK3CA
SCHEMBL6067820 0.91 ABL1 (0.60) ABL1NPC1RAB9ASMN1; SMN2PIK3CA
SCHEMBL6067816 0.91 ABL1 (0.60) ABL1NPC1RAB9ASMN1; SMN2PIK3CA
SCHEMBL6068135 0.91 ABL1 (0.60) ABL1NPC1RAB9ASMN1; SMN2PIK3CA
SCHEMBL6068028 0.90 ABL1 (0.59) ABL1NPC1RAB9ASMN1; SMN2PIK3CA
SCHEMBL6068373 0.90 ABL1 (0.59) ABL1NPC1RAB9ASMN1; SMN2PIK3CA
SCHEMBL6068022 0.90 ABL1 (0.59) ABL1NPC1RAB9ASMN1; SMN2PIK3CA
SCHEMBL6068208 0.84 ABL1 (0.58) ABL1NPC1RAB9ASMN1; SMN2PIK3CA
SCHEMBL6068211 0.84 ABL1 (0.58) ABL1NPC1RAB9ASMN1; SMN2PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7091227-B2 Benzothiazole derivatives ABBOTT GMBH & CO. KG (DE) 2006-08-15 US disclosed
US-20030153568-A1 Benzothiazole derivatives BASF AKTIENGESELLSCHAFT LUDWIGSHAFEN, GERMANY 2003-08-14 US disclosed
EP-1254123-A1 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS Abbott GmbH & Co. KG (DE) 2002-11-06 EP disclosed
WO-2001057008-A1 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153568-A1 Benzothiazole derivatives TK1, FLT1, CDK1 ABL1 7/4885NPC1 3594/4885RAB9A 3285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.